Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Operations: 2009-2024

Historic Cash from Operations for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $103.5 million.

  • Ironwood Pharmaceuticals' Cash from Operations rose 381.37% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year decrease of 45.49%. This contributed to the annual value of $103.5 million for FY2024, which is 43.55% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Cash from Operations is $103.5 million, which was down 43.55% from $183.4 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Cash from Operations ranged from a high of $273.8 million in FY2022 and a low of $103.5 million during FY2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Cash from Operations had a median value of $183.4 million in 2023 and averaged $186.9 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Cash from Operations skyrocketed by 1,474.23% in 2020 and then tumbled by 43.55% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash from Operations (Yearly) stood at $168.8 million in 2020, then skyrocketed by 55.12% to $261.9 million in 2021, then grew by 4.53% to $273.8 million in 2022, then slumped by 33.00% to $183.4 million in 2023, then slumped by 43.55% to $103.5 million in 2024.